Van Strum Towne buys $5,936,599 stake in Amgen (AMGN)

Amgen (AMGN) : Van Strum Towne scooped up 165 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 40,545 shares of Amgen which is valued at $5,936,599.Amgen makes up approximately 3.87% of Van Strum Towne’s portfolio.

Other Hedge Funds, Including , Moors Cabot boosted its stake in AMGN in the latest quarter, The investment management firm added 1,852 additional shares and now holds a total of 26,043 shares of Amgen which is valued at $3,881,449. Amgen makes up approx 0.66% of Moors Cabot’s portfolio.Old Mutual Customised Solutions (proprietary) Ltd reduced its stake in AMGN by selling 1,200 shares or 8.0% in the most recent quarter. The Hedge Fund company now holds 13,800 shares of AMGN which is valued at $2,091,666. Amgen makes up approx 0.60% of Old Mutual Customised Solutions (proprietary) Ltd’s portfolio.Nbt Bank N A Ny reduced its stake in AMGN by selling 620 shares or 13.42% in the most recent quarter. The Hedge Fund company now holds 4,000 shares of AMGN which is valued at $580,720. Amgen makes up approx 0.10% of Nbt Bank N A Ny’s portfolio.Quadrant Capital Group boosted its stake in AMGN in the latest quarter, The investment management firm added 119 additional shares and now holds a total of 2,603 shares of Amgen which is valued at $411,001. Amgen makes up approx 0.26% of Quadrant Capital Group’s portfolio.Eagle Capital Management reduced its stake in AMGN by selling 429 shares or 1.88% in the most recent quarter. The Hedge Fund company now holds 22,441 shares of AMGN which is valued at $3,614,796. Amgen makes up approx 3.94% of Eagle Capital Management’s portfolio.

Amgen closed down -2.13 points or -1.45% at $145.23 with 37,64,649 shares getting traded on Monday. Post opening the session at $147.05, the shares hit an intraday low of $144.9 and an intraday high of $148.35 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Amgen reported $3.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.23 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $2.79. The company had revenue of $5811.00 million for the quarter, compared to analysts expectations of $5702.65 million. The company’s revenue was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.72 EPS.

Many Wall Street Analysts have commented on Amgen. Mizuho Initiated Amgen on Nov 8, 2016 to “Buy”, Price Target of the shares are set at $164.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.